Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $225.42 as of June 9th. ABBV’s trailing and forward P/E were 110.50 and 15.82 respectively according to Yahoo Finance.
Tonhom1009/Shutterstock.com
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. ABBV is positioned as a resilient income-driven healthcare leader that offers stability and upside in a volatile macro environment marked by geopolitical uncertainty surrounding the Middle East conflict.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
While broader equity markets have been choppy and largely directionless, ABBV stands out as a defensive compounder where strong dividend payouts continue to reward investors even in flat or uncertain market conditions.
The company has faced headwinds from the patent expiry of Humira, once its flagship autoimmune therapy, which initially weighed on sentiment and growth expectations. However, its newer immunology portfolio has not only offset this decline but has collectively surpassed Humira’s peak revenue contribution, marking a significant inflection in its earnings power. This transition supports the view that AbbVie has entered a new phase of durable profitability driven by a diversified and expanding therapeutic base.
In addition, the stock has historically exhibited a pattern of consolidation followed by periodic upward re-ratings, suggesting that current weakness tied to macro concerns may be temporary. Even as geopolitical tensions influence short-term sentiment, the healthcare sector’s defensive nature ensures that demand for AbbVie’s medicines remains largely inelastic.
With the S&P 500 trading near prior year-end levels while dividend strategies continue to generate returns, ABBV is increasingly viewed as a reliable income vehicle and capital appreciation potential. Looking ahead, combination of strong free cash flow generation, robust dividend support, and pipeline-driven growth positions AbbVie for constructive re-rating year end, potential for meaningful upside as uncertainty normalizes and investors rotate toward quality defensive growth names.
Previously, we covered a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad in May 2025, highlighted Q1 performance, immunology strength from Skyrizi and Rinvoq, oncology catalyst Elahere with MIRASOL trial, and acquisition-led pipeline. ABBV stock price appreciated approximately 13.57% since our coverage. @MoneyShow shares a similar view but emphasizes income, dividend resilience, and macro-driven re-rating potential amid geopolitical volatility.
AbbVie Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 87 hedge fund portfolios held ABBV at the end of the first quarter which was 84 in the previous quarter. While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
